You're at Wegovy week 7 — here's what's likely happening

Seven weeks in: where you are in the dose ladder

Picture this: it's a Monday morning, you've just injected your seventh pen, and you're wondering whether what you're feeling is normal or a sign something's off. The short answer is almost certainly normal, but it helps to know exactly where week 7 sits in the schedule.

Wegovy follows a graduated titration, typically starting at 0.25 mg for the first four weeks, then moving to 0.5 mg. Week 7 is usually the third week at 0.5 mg. Some people have already been moved to 1.0 mg by their prescriber if tolerability allowed an earlier step; others may be staying a little longer at the current level. That variation is intentional. The prescriber isn't following a calendar rigidly, they're matching the pace to how your body is responding.

If you've just stepped up to 1.0 mg, it's worth knowing this is genuinely a different pharmacological experience for many people. The appetite signal can become noticeably stronger, and nausea or other gastrointestinal symptoms that had faded may reappear for a week or so. This is one of the most common reasons people contact their clinical team around this time, and it's reassuring to hear that it generally settles. Looking back at what was happening at week 5 can help put the changes you're noticing now into perspective. The full week-by-week breakdown for Wegovy covers what typically changes at each stage of the schedule if you want to map the rest of the journey ahead.

Side effects at week 7: what's typical after a dose step

The gastrointestinal profile of semaglutide is well documented. Nausea tends to be the most reported effect, followed by looser stools or constipation, burping, indigestion, and for some people fatigue or headaches. The NHS patient information for semaglutide describes these as common effects, particularly during the early weeks and after dose increases.

At week 7, if you've recently moved to a higher dose, these effects behaving like a brief reset is expected. The stomach is adjusting to a stronger signal to slow emptying. Eating smaller amounts, choosing lower-fat foods, and staying well hydrated are the practical measures most prescribers suggest. Symptoms that are severe, that include intense or persistent abdominal pain spreading to the back, or that come with vomiting you can't keep fluids through, warrant urgent medical attention, the NHS semaglutide medicines page sets out clearly when to seek help. Suspected side effects can be reported through the MHRA Yellow Card scheme.

One thing people sometimes worry about at this stage is whether side effects mean the treatment isn't working. They don't. The biological mechanism (appetite suppression, slower gastric emptying) is the same process that causes the GI discomfort. Both are signs the medicine is active. If side effects feel unmanageable, your prescriber can discuss whether the titration pace needs adjusting; that conversation should happen with them, not by pausing doses on your own.

Weight changes at week 7: realistic expectations

People at week 7 often want a number: how much should I have lost by now? The honest answer is that the trial evidence wasn't designed to answer that question week by week. The pivotal STEP 1 trial (68 weeks, over 1,900 participants) reported an average weight reduction of around 15% across the full treatment period at the 2.4 mg maintenance dose. Those results accumulated over more than a year of treatment, not in the first two months.

At week 7 you're still in what could reasonably be called the calibration phase. Many people do notice some early changes (clothes fitting differently, appetite for snacks reducing) but others see little change on the scales yet and find that frustrating. Both experiences are within the range of what the clinical evidence would predict. The body's response to the appetite signal builds over weeks and months, and the higher maintenance doses do more of the heavy lifting later in the schedule. Checking your progress at this stage against the eventual outcome of the trial would be measuring the wrong thing at the wrong time.

If you're curious about how results tend to develop as treatment progresses, the week 9 page covers what typically shifts as people settle into the 1.0 mg phase, and the broader semaglutide treatment overview puts the full evidence picture in context.

Practical things worth checking at the seven-week mark

Week 7 is a good moment to run through a few housekeeping points that matter for the long term. Injection technique: are you rotating sites between abdomen, thigh, and upper arm? Staying at the same spot repeatedly can cause skin changes that affect absorption. Storage: pens should be kept refrigerated between 2°C and 8°C; the exact window for room-temperature use is in your Patient Information Leaflet, and it's shorter than most people assume.

Timing is worth a mention too. Some people find that their injection day lands on a bank holiday, a holiday abroad, or (occasionally) the week they just forgot because payday chaos swallowed the morning routine. A single delayed injection is rarely catastrophic, but the specific guidance on what to do if you miss or delay a dose is in your leaflet and should be followed rather than improvised. Your prescriber can also advise.

If you started treatment through a private route and want to review how things are going, the general FAQs cover common mid-treatment questions. For those still considering starting, understanding the weight-loss treatment options available in the UK is a sensible first step, and for Wegovy specifically, the how to access Wegovy page explains the clinical assessment process. At this stage in your treatment, the most useful thing is an honest conversation with whoever is prescribing for you; if that's through nume, our prescribers review queries seven days a week. Check your eligibility if you haven't yet started and want to understand whether Wegovy could be right for you.